Culture Medium Contains A Growth Factor Or Growth Regulator Patents (Class 435/384)
-
Patent number: 8137969Abstract: The present invention relates to undifferentiated human embryonic stem cells, methods of cultivation and propagation and production of differentiated cells. In particular it relates to the production of human ES cells capable of yielding somatic differentiated cells in vitro, as well as committed progenitor cells such as neural progenitor cells capable of giving rise to mature somatic cells including neural cells and/or glial cells and uses thereof.Type: GrantFiled: June 13, 2008Date of Patent: March 20, 2012Assignee: ES Cell International PTE Ltd.Inventors: Benjamin Eithan Reubinoff, Martin Frederick Pera, Tamir Ben-Hur
-
Patent number: 8129186Abstract: The present invention is directed to the use of choroid plexus cells and/or choroid plexus conditioned media for enhancing the growth, survival and/or maintenance of function of non-choroid plexus cells grown in long term or short term culture.Type: GrantFiled: April 18, 2006Date of Patent: March 6, 2012Assignee: Neurotrophincell Pty, LimitedInventors: Robert Bartlett Elliott, Stephen John Martin Skinner, Livia Del Carmen Escobar Orellana, Christopher Thanos
-
Patent number: 8101409Abstract: Compositions for promoting growth and/or differentiation of a stem cell are disclosed. The composition comprises: a) a diamond film; b) a stem cell cultured on the diamond film; and c) a medium bathing the stem cell. The stem cell may be a mammalian neural stem cell and the diamond film may comprise a hydrogen-terminated or an oxygen-terminated surface. The hydrogen-terminated surface promotes proliferation and differentiation of a neural stem cell into neurons, and the oxygen-terminated surface promotes a neural stem cell to proliferate and differentiate into oligodendrocytes.Type: GrantFiled: October 5, 2009Date of Patent: January 24, 2012Assignees: National Health Research Institutes, National Tsing Hua UniversityInventors: Ing-Ming Chiu, Ying-Chieh Chen, Don-Ching Lee, Nyan-Hwa Tai
-
Patent number: 8071380Abstract: The present invention discloses the isolation and characterization of cells isolated either from adult skeletal muscle or from adult cardiac muscle. These cells are used for the treatment of muscular disorders including muscular dystrophy and cardiopathics, respectively.Type: GrantFiled: February 15, 2007Date of Patent: December 6, 2011Assignee: Fondazione Centro San Raffaele Del Monte TaborInventors: Giulio Cossu, Beatriz Galvez Gonzales, Rossana Tonlorenzi
-
Patent number: 8071375Abstract: The use of certain IL-6-type cytokines for the in vitro maturation of mammalian oocytes is described. The in vitro matured oocytes may be used in in vitro fertilization protocols.Type: GrantFiled: November 26, 2004Date of Patent: December 6, 2011Assignee: Merck Serono SAInventors: Ann M. Clark, Daniel Gustavo de Matos, Jennifer A. Jackson, Stephen S. Palmer, Cam Anh T. Tran
-
Patent number: 8067233Abstract: The present disclosure describes mammalian pluripotent embryonic-like stem cells (ELSCs) isolated from corneal limbal tissue, a non-embryonic tissue. The ELSCs of the present disclosure are capable of proliferating in an in vitro culture, maintain the potential to differentiate into cells of endoderm, mesoderm, and ectoderm lineage in culture, and are capable of forming embryoid-like bodies when placed in suspension culture. Thus, these cells possess multi-lineage differentiation potential and self-renewing capability. ELSCs may be a promising therapeutic tool, and may provide new therapeutic alternatives for various diseases, conditions, and injuries.Type: GrantFiled: January 16, 2009Date of Patent: November 29, 2011Assignee: Reliance Life Science PVT. Ltd.Inventors: Satish Mahadeorao Totey, Subhadra Devi Kashyap, Khan Firdos Alam, Pai Rajarshi, Khanna Aparna, Tipnis Shabri, Geeta Ravindran
-
Patent number: 8058066Abstract: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.Type: GrantFiled: November 30, 2009Date of Patent: November 15, 2011Assignee: Stemnion, Inc.Inventors: Vivienne S. Marshall, Charlotte A. Smith, Catherine J. Trumpower, George L. Sing, Linda O. Palladino
-
Patent number: 8058063Abstract: A method of priming neural stem cells in vitro by adhesively culturing in a mixture of basic fibroblast growth factor, laminin and heparin to differentiate into specific neuronal phenotypes, including cholinergic, glutamatergic and GABAergic neurons, in a region-specific manner, when transplanted in vivo.Type: GrantFiled: June 19, 2002Date of Patent: November 15, 2011Assignee: Board of Regents, The University of Texas SystemInventor: Ping Wu
-
Patent number: 8026096Abstract: Disclosed and claimed is a human erythropoietin (EPO) expressed and produced in Spodoptera frugiperda Sf900+ cell line (ATCC: CRL 12579) transfected with a baculovirus construct containing the EPO gene. The EPO has an in vivo activity of 200,000 U/mg to 500,000 U/mg.Type: GrantFiled: January 18, 2000Date of Patent: September 27, 2011Assignee: Protein Sciences CorporationInventors: Gale E. Smith, John Knell, Andrei I. Voznesensky
-
Patent number: 8017390Abstract: A method for the preparation of dermal papilla tissue comprising the step of culturing mesenchymal stem cells in a medium having a specific composition is provided. The method makes it possible to form in vitro a quantity of dermal papilla tissues having hair follicle inducting ability and, accordingly, it can be effectively used for the treatment of alopecia through cell transplantation.Type: GrantFiled: July 20, 2007Date of Patent: September 13, 2011Assignee: Dongguk University Industry-Academic Cooperation FoundationInventors: Jung-Keug Park, Hee-Hoon Yoon, Bo-Young Yoo, Young-Jin Kim, Youn-Ho Shin
-
Patent number: 8008075Abstract: The present invention relates to methods for production of undifferentiated or differentiated embryonic stem cell aggregate suspension cultures from undifferentiated or differentiated embryonic stem cell single cell suspensions and methods of differentiation thereof.Type: GrantFiled: November 4, 2008Date of Patent: August 30, 2011Assignee: ViaCyte, Inc.Inventors: Chad Green, Xiaojie Yu, Anne Bang, Eugene Brandon, Olivia Kelly, Alan D. Agulnick, E. Edward Baetge, Kevin A. D'Amour, Thomas C. Schulz, Allan J. Robins
-
Patent number: 7993917Abstract: Methods for the diagnosis of visceral, cutaneous and canine leishmaniasis in a subject suspected of being infected with the parasitic protozoa Leishmania is disclosed. Disclosed are antibody-capture enzyme-linked immunosorbent assays (ELISAs) for the detection of antibodies to Leishmania parasite soluble antigens and antigen-capture ELISAs for the detection of Leishmania parasite soluble antigens in host samples. Also disclosed are immunodiagnostic kits for the detection of Leishmania parasite circulating antigens or IgM and IgG antibodies in a sample from subject having visceral, cutaneous or canine leishmaniasis. In these methods and kits, detection may be done photometrically or visually. The methods and kits also allow the visualization of Leishmania amastigotes or promastigotes in a sample.Type: GrantFiled: August 20, 2009Date of Patent: August 9, 2011Assignee: The United States of America as represented by the Secretary of the ArmyInventor: Samuel K. Martin
-
Patent number: 7989178Abstract: A system combining a clonogenic differentiation assay with an instrument-based ATP bioluminescence proliferation assay to produce a standardized colony-forming stem and progenitor cell potency assay is provided.Type: GrantFiled: June 6, 2008Date of Patent: August 2, 2011Assignee: Hemogenix, Inc.Inventor: Ivan N. Rich
-
Patent number: 7977096Abstract: The invention provides media formulations. A complete media formulation of the invention includes, for example, the following components: albumin, an iron carrier, glutamine, a glycosidase or hydrolase, fibroblast growth factor (FGF), a salt or mineral, and essential amino acids, at an osmolarity of about 220-330 mOsm/Liter.Type: GrantFiled: January 3, 2008Date of Patent: July 12, 2011Assignee: California Stem Cell, Inc.Inventor: Gabriel Nistor
-
Publication number: 20110165132Abstract: The invention relates to heparan sulphate GAGs obtained by affinity chromatography using the heparin-binding domain of BMP2. The GAGs were obtained from osteoblast extracellular matrix and from a commercially available heparan sulfate (Celsus HS).Type: ApplicationFiled: September 11, 2009Publication date: July 7, 2011Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventors: Simon McKenzie Cool, Victor Nurcombe, Christian Dombrowski
-
Patent number: 7964397Abstract: The present invention relates to a method for the cultivation of primary cells. The primary cells are cultivated in a serum free medium comprising a factor selected from the group consisting of growth factors and attachment factors. The method for the cultivation of primary cells may be one step in a method for the amplification of viruses, such as poxviruses. According to this latter method the primary cells are cultivated in a serum free medium comprising a factor selected from the group consisting of growth factors and attachment factors. The cells are then infected with the virus and the infected cells are cultivated in serum free medium until progeny virus is produced.Type: GrantFiled: October 1, 2008Date of Patent: June 21, 2011Assignee: Bavarian Nordic A/SInventors: Ingmar Rathe, Eva Felder, Karl Heller
-
Patent number: 7964398Abstract: The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost innoculation regimen. The present invention relates to a method of virus amplification in primary cells which are cultivated in a serum free medium. Viruses produced by this method are advantageously free of any infectious agents comprised in animal sera.Type: GrantFiled: July 14, 2010Date of Patent: June 21, 2011Assignee: Bavarian Nordic A/SInventors: Paul Chaplin, Paul Howley, Christine Meisinger-Henschel, Ingmar Rathe, Eva Felder, Karl Heller
-
Patent number: 7964395Abstract: The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost inoculation regimen. The present invention relates to a method of virus amplification in primary cells which are cultivated in a serum free medium. Viruses produced by this method are advantageously free of any infectious agents comprised in animal sera.Type: GrantFiled: August 28, 2008Date of Patent: June 21, 2011Assignee: Bavarian Nordic A/SInventors: Paul Chaplin, Paul Howley, Christine Meisinger-Henschel, Ingmar Rathe, Eva Felder, Karl Heller
-
Patent number: 7964396Abstract: The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost inoculation regimen. The present invention relates to a method of virus amplification in primary cells which are cultivated in a serum free medium. Viruses produced by this method are advantageously free of any infectious agents comprised in animal sera.Type: GrantFiled: August 28, 2008Date of Patent: June 21, 2011Assignee: Bavarian Nordic A/SInventors: Paul Chaplin, Paul Howley, Christine Meisinger-Henschel, Ingmar Rathe, Eva Felder, Karl Heller
-
Patent number: 7959939Abstract: A laminate comprising a transparent collagen I type sheet and a human corneal endothelial cell culture layer provided on the sheet. An endothelial cell culture layer laminate usable in transplantation is provided.Type: GrantFiled: February 17, 2005Date of Patent: June 14, 2011Inventors: Satoru Yamagami, Tatsuya Mimura, Shiro Amano, Keisuke Tanaka, Shunji Hattori, Shinkichi Irie, Yasuhiro Osakabe
-
Patent number: 7955852Abstract: Ex vivo and in vivo methods of expansion of renewable stem cells, expanded populations of renewable stem cells and their uses.Type: GrantFiled: February 9, 2004Date of Patent: June 7, 2011Assignee: Gamida Cell Ltd.Inventors: Tony Peled, Avi Treves, Oren Rosen
-
Patent number: 7951591Abstract: Methods for obtaining pluripotent (embryonic stem) cells from parthenogenetic embryos, especially primates, are provided. These cells are useful for producing differentiated cells, tissues and organs, especially human and non-human primate cells, tissues and organs.Type: GrantFiled: February 27, 2003Date of Patent: May 31, 2011Assignee: Advanced Cell Technology, Inc.Inventors: James M. Robl, Jose Cibelli, Amy Burnside
-
Patent number: 7947498Abstract: The present invention provides undifferentiated human embryonic stem cells, methods of cultivation and propagation and production of differentiated cells. In particular it relates to the production of human ES cells capable of yielding somatic differentiated cells in vitro, and committed progenitor cells such as neural progenitor cells capable of giving rise to mature somatic cells including neural cells and/or glial cells and uses thereof. The invention also provides methods that generate in vitro and in vivo models of controlled differentiation of ES cells towards the neural lineage. The model, and the cells that are generated along the pathway of neural differentiation may be used for the study of the cellular and molecular biology of human neural development, for the discovery of genes, growth factors, and differentiation factors that play a role in neural differentiation and regeneration, for drug discovery and for the development of screening assays for teratogenic, toxic and neuroprotective effects.Type: GrantFiled: February 6, 2009Date of Patent: May 24, 2011Assignee: ES Cell International PTE Ltd.Inventors: Benjamin Eithan Reubinoff, Martin Frederick Pera, Tamir Ben-Hur
-
Patent number: 7939322Abstract: The present invention is directed to pluripotent cells that can be readily expanded in culture on tissue culture substrate that is not pre-treated with protein or an extracellular matrix, and do not require a feeder cell line. The present invention also provides methods to derive the pluripotent cell line from human embryonic stem cells.Type: GrantFiled: April 24, 2008Date of Patent: May 10, 2011Assignee: Centocor Ortho Biotech Inc.Inventor: Alireza Rezania
-
Publication number: 20110104754Abstract: We describe a method of growing an animal cell in a culture medium, in which the culture medium comprises an elevated concentration of a thymidine family member, in which the growth or viability of the animal cell is increased as a result of the elevated concentration of the thymidine family member in the cell culture medium. Preferably, the cell culture medium comprises a semi-solid medium, which is a serum free or chemically defined medium.Type: ApplicationFiled: January 11, 2011Publication date: May 5, 2011Inventors: Irene Bramke, Julian Francis Burke
-
Publication number: 20110064705Abstract: Methods of generating and expanding human hemangio-colony forming cells and non-engrafting hemangio cells in vitro and methods of expanding and using such cells are disclosed. The methods permit the production of large numbers of hemangio-colony forming cells, non-engrafting hemangio cells as well as derivative cells, such as hematopoietic and endothelial cells. The cells obtained by the methods disclosed may be used for a variety of research, clinical, and therapeutic applications. Human non-engrafting hemangio cells are a novel progenitor cell population that is related to but distinct from the hemangioblast and human hemangio-colony forming cells. The invention also provides compositions, preparations, and solutions comprising hemangio-colony forming cells, non-engrafting hemangio cells or cells differentiated therefrom.Type: ApplicationFiled: May 6, 2009Publication date: March 17, 2011Applicant: ADVANCED CELL TECHNOLOGY, INC.Inventors: Robert Lanza, Shi-Jiang Lu
-
Patent number: 7901937Abstract: A continuous flow bioreactor system that includes a bioreactor, an optional post-bioreactor preparation chamber, a cell sorter, and an optional pre-bioreactor preparation chamber in a closed loop, useful for enriching a heterogeneous cell population growing in the bioreactor with an isolated subpopulation of cells.Type: GrantFiled: November 3, 2008Date of Patent: March 8, 2011Assignee: Regents of the University of MinnesotaInventors: Friedrich Srienc, Abdelqader Zamamiri, Nicholas R. Abu-Absi, James A. Kacmar
-
Patent number: 7897389Abstract: This invention provides a new procedure for generating cardiomyocyte lineage cells from embryonic stem cells for use in regenerative medicine. Differentiating by way of embryoid body formation or in serum is no longer required. Instead, the stem cells are plated onto a solid substrate, and differentiated in the presence of select factors and morphogens. After enrichment for cells with the appropriate phenotype, the cells are allowed to cluster into Cardiac Bodies™, which are remarkably homogeneous and suitable for the treatment of heart disease.Type: GrantFiled: September 15, 2008Date of Patent: March 1, 2011Assignee: Geron CorporationInventors: Joseph D. Gold, Mohammad Hassanipour, Lila R. Collins, Chunhui Xu
-
Patent number: 7892830Abstract: While culture medium and systems have been described that permit the culture and proliferation of human embryonic stem cells in feeder free and animal product free conditions, these conditions will not readily support cloning of an embryonic stem cell culture meaning, at least here, the initiation of a sub-culture using one or a very few originating cells. It has been found here that a class of small molecules that are inhibitors of kinase enzymes will increase the efficiency of cloning of stem cell cultures sufficiently to make such cloning practical in the defined medium and in other media as well.Type: GrantFiled: January 17, 2008Date of Patent: February 22, 2011Assignee: Wisconsin Alumni Research FoundationInventors: Veit Bergendahl, James A. Thomson
-
Patent number: 7883861Abstract: The present invention relates generally to kits that provide reagent mixes and instructions for the use thereof, in performing high-throughput assay methods that determine the proliferative status of isolated target cell populations. The methods measure the luminescent output derived from the intracellular ATP content of incubated target cells, and correlate the luminescence with the proliferative status of the cells. The present invention further relates to kits that provide reagent mixes and instructions for high-throughput assays methods for screening compounds that may modulate the proliferative status of a target cell population. The kits of the present invention and methods therein described may be used for determining the proliferative status of any isolated cell line or type. The kits and methods of the present invention address the need for rapid assays that determine the proliferative status of isolated hematopoietic stem and progenitor cells and of subpopulations of differentiated cells thereof.Type: GrantFiled: March 17, 2008Date of Patent: February 8, 2011Assignee: HemoGenix, Inc.Inventor: Ivan N. Rich
-
Publication number: 20110003358Abstract: Cultures of cells immunoreactive for glial fibrillary acidic protein (GFAP), as well as for the intermediate filament marker nestin were grown in a medium including epidermal growth factor (EGF) and serum. The cultured cells had the morphology of astroglial cells. The cells can be proliferated in adherent or suspension cultures. Depending on the culture conditions, the cells can be induced to differentiate to neurons or glial cells. The cultures can be expanded over a large number of passages during several months, and survive, express an astroglial phenotype and integrate well after transplantation into both neonatal and adult rat forebrain.Type: ApplicationFiled: December 23, 2009Publication date: January 6, 2011Applicant: NsGene A/SInventors: Lars Wahlberg, Kenneth Campbell, Charlotta Skogh, Cecilia Ericksson, Klas Wictorin
-
Patent number: 7846726Abstract: This invention discloses a substantially pure population of human urinary bladder-derived epithelial cells and methods of isolating and culturing the urinary bladder-derived epithelial cells. In addition, several uses of human urinary bladder-derived epithelial cells and cells differentiating therefrom are disclosed herein.Type: GrantFiled: February 12, 2003Date of Patent: December 7, 2010Assignee: Raven biotechnologies, inc.Inventors: Ronghao Li, Zhuangyu Pan
-
Publication number: 20100303767Abstract: The invention provides for a method for aggregating dermal papilla cells or dermal sheath cells or a combination thereof, the method comprising: growing dermal papilla cells or dermal sheath cells or a combination thereof in suspension culture; and contacting the culture with an effective amount of an enzyme, wherein a substrate of the enzyme is an extracellular matrix molecule in the suspension culture, so as to aggregate dermal papilla cells or dermal sheath cells. The culture may be a hanging drop culture and the enzyme may be a hyaluronidase.Type: ApplicationFiled: February 28, 2007Publication date: December 2, 2010Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Angela M. Christiano, Colin A.B. Jahoda
-
Patent number: 7829332Abstract: The present invention relates to a method of inhibiting differentiation of a population of neural stem cells by contacting a purinergic receptor agonist and a population of neural stem cells under conditions effective to inhibit differentiation of the population of neural stem cells. Another aspect of the present invention relates to a method of producing neurons and/or glial cells from a population of neural stem cells by culturing a population of neural stem cells with a purinergic receptor antagonist under conditions effective to cause the neural stem cells to differentiate into neurons and/or glial cells. The purinergic receptor agonist can also be used in a method of inducing proliferation and self-renewal of neural stem cells in a subject and a method of treating a neurological disease or neurodegenerative condition in a subject. The purinergic receptor antagonist can also be used in treating a neoplastic disease of the brain or spinal cord in a subject.Type: GrantFiled: February 10, 2005Date of Patent: November 9, 2010Assignees: Cornell Research Foundation, Inc., New York Medical CollegeInventors: Steven A. Goldman, Maiken Nedergaard, Jane Lin
-
Publication number: 20100279412Abstract: Disclosed are: a culture medium containing a specific growth factor and at least one phospholipid; a composition for preparation of the culture medium; a kit; and a method. A technique can be provided which uses a serum-free or low-serum culture medium and has a promoting effect on the proliferation of an animal cell comparable to the promoting effect obtained by the culture in a serum-containing culture medium.Type: ApplicationFiled: January 11, 2007Publication date: November 4, 2010Applicants: JAPAN SCIENCE AND TECHNOLOGY AGENCY, TWO CELLS CO. LTD.Inventors: Yukio Kato, Jin Chang Shao, Yuki Katsura, Koichiro Tsuji
-
Patent number: 7824912Abstract: The present invention is directed to methods for readily propagating somatic liver stem cells. The methods comprise enhancing guanine nucleotide (GNP) biosynthesis, thereby expanding guanine nucleotide pools. This in turn conditionally suppresses asymmetric cell kinetics in the explanted cells. The methods of the invention include pharmacological methods and genetic methods. For example, the resulting cultured somatic liver stem cells can be used for a variety of applications including cell replacement therapies, gene therapies, drug discovery applications, and tissue engineering applications, such as the generation of artificial liver.Type: GrantFiled: June 21, 2006Date of Patent: November 2, 2010Assignee: Massachusetts Institute of TechnologyInventors: James L. Sherley, Krisha Panchalingam
-
Patent number: 7807461Abstract: This invention relates to human adipose tissue-derived multipotent adult stem cells. More particularly, the invention relates to human adipose tissue-derived multipotent stem cells, which can be maintained in an undifferentiated state for a long period of time by forming spheres and have high proliferation rates, as well as methods for isolating and maintaining the adult stem cells, and methods for differentiating the multipotent adult stem cells into nerve cells, fat cells, cartilage cells, osteogenic cells and insulin-releasing pancreatic beta-cells. Also, the invention relates to cellular therapeutic agents for treating osteoarthritis, osteoporosis and diabetes and for forming breast tissue, which contain the differentiated cells or the adult stem cells.Type: GrantFiled: December 20, 2005Date of Patent: October 5, 2010Assignee: RNL Bio Co., LtdInventors: Kyung Sun Kang, Jeong Chan Ra, Jung Ran Park
-
Patent number: 7795026Abstract: The invention is directed to novel cells that are derived from human embryoid bodies. Such embryoid body-derived (EBD) cells are relatively uncommitted or progenitor (e.g., pluripotent) cells. EBD cells, while not immortal, display long-term proliferation in culture with a normal karyotype and can be cryopreserved and cloned. They can be efficiently transfected with retroviruses and lentivirus and genetically manipulated. Although they have a developmentally broad multilineage expression profile, they do not form tumors when injected into severe combined immunodeficiency (SCID) mice. As a result, EBD cells have a variety of uses, for example, in transplantation therapies.Type: GrantFiled: January 22, 2001Date of Patent: September 14, 2010Assignee: The Johns Hopkins University School of MedicineInventors: Michael J. Shamblott, John D. Gearhart
-
Patent number: 7795024Abstract: The present invention provides an apparatus and methods for expansion of hematopoietic stem cell numbers. The stem cells are cultured and differentiated cells and endogenous growth factors are removed (depleted), permitting long term culture and expansion of the stem cells. The hematopoietic stem cells are used in numerous therapeutic procedures.Type: GrantFiled: May 3, 2004Date of Patent: September 14, 2010Assignee: Insception Bioscience, Inc.Inventors: Gerard Madlambayan, Peter Zandstra
-
Patent number: 7790456Abstract: The invention relates to a process for cultivating undifferentiated stem cells in suspension and in particular to a method for cultivating stem cells on microcarriers in vessels. The method enables stem cells to be cultivated in a scalable process for the first time, without losing their pluripotentiality. Different types of vessels are suitable for cultivation, such as e.g. spinners and bioreactors. The option of precisely setting the cultivation conditions in said vessels aids the process of obtaining a pluripotentiality of the stem cells. the inventive method also permits large yields of stem cells of an unvarying quality to be produced.Type: GrantFiled: September 9, 2005Date of Patent: September 7, 2010Assignee: Rheinische Friedrich-Wilhelms-UniversitatInventors: Stefanie Terstegge, Oliver Brüstle
-
Patent number: 7790458Abstract: The invention provides populations of expanded CD34-expressing cells and methods of use. Particular embodiments provide for defined culture media useful for growing these cells, and grafts comprising these cells. The invention finds use in methods for reconstituting, repairing, and regenerating tissue damage.Type: GrantFiled: May 13, 2005Date of Patent: September 7, 2010Assignee: Becton, Dickinson and CompanyInventors: Ruiling Xu, Andrea Liebmann-Vinson, Keith DeLuca, Mohammad Heidaran
-
Patent number: 7776597Abstract: The present invention provided a simple three-step approach based on the combinational induction with activin A, all-trans retinoic acid and, optionally, other maturation factors which are able to induce embryonic stem cells to differentiate into insulin-producing cells. A kit used to induce embryonic stem cells to differentiate into insulin-producing cells was also provided.Type: GrantFiled: April 14, 2006Date of Patent: August 17, 2010Assignee: Beijing Hua Yuan Bo Chuang Technology LimitedInventors: Hongkui Deng, Mingxiao Ding, Yan Shi, Wei Jiang, Lingling Hou, Fuchou Tang
-
Patent number: 7772001Abstract: Methods are described for mapping a pathway of differentiation of a population of embryonic cells that includes exposing the cells to an exogenous factor and measuring gene expression products that are characteristic of a particular cell type or lineage. Directing differentiation of human embryonic cells relies on dissociated embryoid bodies that are then exposed to one or more exogenous factors to enrich a culture for a particular cell type. The differentiated cells may be used for treating a medical condition in a human. Kits for determining differentiation pathways and screening exogenous factors for their utility in differentiation are provided.Type: GrantFiled: January 3, 2006Date of Patent: August 10, 2010Assignee: Yissum Research Development Company Of the Hebrew University of JerusalemInventor: Nissim Benvenisty
-
Publication number: 20100197019Abstract: A method for culture of hair follicular dermal sheath cells or precursor cells thereof which are potent cellular materials for such as hair regeneration by cell transplantation is provided. That is, by performing culture in an animal cell culture medium supplemented with platelet-derived growth factor AA (PDGF-AA) and fibroblast growth factor 2 (FGF2), hair follicular dermal sheath cells are proliferated while sustaining their function, or hair follicular dermal sheath precursor cells are differentiated into dermal sheath cells and proliferated.Type: ApplicationFiled: October 2, 2006Publication date: August 5, 2010Inventors: Koei Toyoshima, Mikaru Matsunaga, Katsutoshi Yoshizato
-
Patent number: 7763464Abstract: This invention provides populations human cells of the cardiomyocyte lineage. The cells are obtained by causing cultures of pluripotent stem cells to differentiate in vitro, and then harvesting cells with certain phenotypic features. Differentiated cells bear cell surface and morphologic markers characteristic of cardiomyocytes, and a proportion of them undergo spontaneous periodic contraction. Highly enriched populations of cardiomyocytes and their replicating precursors can be obtained, suitable for use in a variety of applications, such as drug screening and therapy for cardiac disease.Type: GrantFiled: January 21, 2005Date of Patent: July 27, 2010Assignee: Geron CorporationInventor: Chunhui Xu
-
Patent number: 7763462Abstract: Compositions and methods are provided for enhancing the survival and promoting the maturation of mammalian oocytes, zygotes and preimplantation embryos. BDNF or BDNF agonists may be administered to an individual, or to cells in vitro, to enhance cellular maturation, embryo growth and fertilization. Accordingly, compositions comprising BDNF are herein presented for use in promoting in vivo oocyte maturation as well as for use as a component in culture media for promoting preimplantation maturation of zygotes and embryos, for instance, for use with in vitro fertilization procedures and for the production of stem cells. Additionally, compounds that interfere with the binding of BDNF to its receptor may be administered to an individual to prevent oocyte maturation, thereby acting as a contraceptive. The BNDF receptor, TrkB, and BDNF also find use in the screening and design of agonists and antagonists for use in the methods of the invention.Type: GrantFiled: June 13, 2007Date of Patent: July 27, 2010Assignees: The Board of Trustees of the Leland Stanford Junior University, N.V. OrganonInventors: Kazuhiro Kawamura, Aaron J. W. Hsueh, Sabine M. Mulders
-
Patent number: 7749758Abstract: The present invention relates to human, rat and mouse stem cell-derived neuron survival factor polypeptides (SDNSF), a process for producing them, cDNA encoding SDNSF, a vector comprising the cDNA, host cells transformed by the vector, an antibody against SDNSF, pharmaceutical compositions containing SDNSF or the antibody, a method of assaying SDNSF, a reagent for assaying SDNSF, and a screening method using SDNSF. The polypeptides are effective in the survival of nerve cells and, therefore, efficacious in treating injury to the central nerve system caused by brain infarction, brain hemorrhage, spinal cord injury, etc.Type: GrantFiled: August 17, 2007Date of Patent: July 6, 2010Assignees: Ono Pharmaceutical Co., Ltd.Inventors: Tasuku Honjo, Kei Tashiro, Jun Takahashi, Hiroki Toda
-
Patent number: 7732201Abstract: A method for producing a neuroblast and a cellular composition comprising an enriched population of neuroblast cells is provided. Also disclosed are methods for identifying compositions which affect neuroblasts and for treating a subject with a neuronal disorder, and a culture system for the production and maintenance of neuroblasts.Type: GrantFiled: November 3, 2006Date of Patent: June 8, 2010Assignee: The Regents of the University of CaliforniaInventors: Fred H. Gage, Jasodhara Ray
-
Publication number: 20100136512Abstract: The disclosure relates to the use of culture media containing thyroid hormones or analogs thereof, and includes methods and uses thereof for embryo culture, embryo production, embryo maturation, improved survival of embryos and improved viability of embryos post cryopreservation.Type: ApplicationFiled: October 20, 2009Publication date: June 3, 2010Inventors: William Allan King, Fazl A. Ashkar
-
Patent number: RE41974Abstract: A biochemically defined culture medium for culturing engineered Chinese hamster ovary (CHO) cell lines, which is essentially free from protein, lipid and carbohydrate isolated from an animal source, having water, an osmolality regulator, a buffer, an energy source, amino acids including L-glutamine, an inorganic or recombinant iron source, and a synthetic or recombinant growth factor, and optionally non-ferrous metal ions vitamins and cofactors. Also cells adapted to grow in such a culture medium.Type: GrantFiled: December 15, 2006Date of Patent: November 30, 2010Assignee: GlaxoSmithKline LLCInventors: Michael John Keen, Nicholas Timothy Rapson